I agree with one possible exception. In my limited trading experience, I've noticed that manipulation starts to taper off once a small biocap inks a significant partnership with a BP.

If GC can uplist as a result of a major partnership announcement with a BP, I'm not going to be anticipating a whole lot of shorting and manipulation. Keep in mind, Lympro revenue is just around the corner. IMHO, if you combine imminent revenue with a major JV announcement, manipulators will want to find an easier target to attack.